Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology ...

BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Comp ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

PALO ALTO, Calif., Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics ...

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a sell rating to a hold rating in a ...

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer.